Compare TWIN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | CRBP |
|---|---|---|
| Founded | 1918 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 202.6M |
| IPO Year | N/A | N/A |
| Metric | TWIN | CRBP |
|---|---|---|
| Price | $15.79 | $10.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $50.29 |
| AVG Volume (30 Days) | 30.0K | ★ 280.2K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $347,837,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | $100.00 |
| P/E Ratio | $841.48 | ★ N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $4.64 |
| 52 Week High | $17.08 | $20.56 |
| Indicator | TWIN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 36.05 |
| Support Level | $15.44 | $10.10 |
| Resistance Level | $16.27 | $10.82 |
| Average True Range (ATR) | 0.61 | 0.68 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 85.85 | 8.91 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.